Fcpm Iii Services B.V. Acquires 3,237,714 Shares of Vor Biopharma Inc. $VOR

Fcpm Iii Services B.V. increased its holdings in Vor Biopharma Inc. (NASDAQ:VOR) by 852.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,617,354 shares of the company’s stock after acquiring an additional 3,237,714 shares during the period. Vor Biopharma comprises 6.3% of Fcpm Iii Services B.V.’s investment portfolio, making the stock its 6th biggest holding. Fcpm Iii Services B.V. owned 34.75% of Vor Biopharma worth $47,315,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. purchased a new stake in Vor Biopharma in the 4th quarter valued at about $33,275,000. NEXTBio Capital Management LP purchased a new stake in Vor Biopharma in the 4th quarter valued at about $13,080,000. UBS Group AG increased its stake in Vor Biopharma by 284.8% in the 4th quarter. UBS Group AG now owns 292,118 shares of the company’s stock valued at $3,821,000 after buying an additional 216,209 shares during the last quarter. Jane Street Group LLC purchased a new stake in Vor Biopharma in the 1st quarter valued at about $140,000. Finally, Geode Capital Management LLC increased its stake in Vor Biopharma by 578.3% in the 4th quarter. Geode Capital Management LLC now owns 185,808 shares of the company’s stock valued at $2,432,000 after buying an additional 158,416 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on VOR. Wall Street Zen lowered shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. HC Wainwright reissued a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Wedbush increased their target price on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Monday, June 1st. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

Insider Transactions at Vor Biopharma

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the sale, the director owned 2,402,095 shares in the company, valued at $37,881,038.15. This represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 3,002,903 shares of company stock worth $49,412,176. Insiders own 0.27% of the company’s stock.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $14.11 on Wednesday. Vor Biopharma Inc. has a twelve month low of $4.06 and a twelve month high of $65.80. The firm has a 50 day moving average price of $14.93 and a 200-day moving average price of $14.03.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. On average, research analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).